<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02522130</url>
  </required_header>
  <id_info>
    <org_study_id>ob/gyn4</org_study_id>
    <nct_id>NCT02522130</nct_id>
  </id_info>
  <brief_title>Different Analgesics Prior to Intrauterine Device (IUD) Insertion: Is There Any Evidence?</brief_title>
  <official_title>Different Analgesics Prior to IUD Insertion: Is There Any Evidence?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Al Hayat National Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Menoufia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Al Hayat National Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Different ways of reducing pain during IUD insertion have been explored. So a randomized
      study will be conducted to test their role
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized clinical controlled trial of women undergoing IUD insertion. Participants in the
      study groups will be randomly assigned by labeled opaque envelopes to either1% lidocaine
      (Xylocaine 1%, Astra Zeneca, Egypt), misoprostol (Sigma, Egypt), naproxen (Naprosyn, Syntax,
      Egypt) or placebo tablets.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>current pain level with IUD insertion and 15 minutes post procedure measured by the Visual Analogue Scale.</measure>
    <time_frame>15 minutes</time_frame>
    <description>A Visual Analogue Scale is a measurement instrument that tries to measure a characteristic or attitude that is believed to range to across a continuum of values and can not easily to be directly measured. Subjects pain using a 10 point visual analogue scale (-+VAS, anchors: 0=non, 10 = worst imaginable).
The participants were asked to mark their pre IUD insertion pain expectancies initially, then to mark their pain during different steps of IUD placement.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>IUD Insertion Complication</condition>
  <arm_group>
    <arm_group_label>lidocaine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A will receive 10 ml 1% lidocaine (Xylocaine 1%, Astra Zeneca, Egypt) Para cervical block prior to insertion of IUD (injection sites at cervix-vaginal junction typically at 4 ,8 O'clock), Then 3 minutes waiting period between the administration of the Para cervical block and IUD insertion,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>misoprostol group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group B will receive 400 mcg oral misoprostol (Sigma, Egypt) prior to IUD insertion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non steroid group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group C will receive oral naproxen (Naprosyn, Syntax, Egypt) prior to IUD insertion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>group D will receive placebo tablets.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>intracervical injection</description>
    <arm_group_label>lidocaine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral misoprostol</intervention_name>
    <description>oral treatment</description>
    <arm_group_label>misoprostol group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naproxen</intervention_name>
    <description>oral treatment</description>
    <arm_group_label>non steroid group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>oral treatment</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients are considered eligible if:

          1. they are alert oriented and co-operative to response to the visual analogue scale
             (VAS).

          2. They will sign the informed consent to participate in the clinical trial before
             entering the study.

          3. Willingness to be randomized and complete study questionnaires.

        Exclusion Criteria:

        Participants are excluded from participation if they are ineligible for an IUD by accepted
        criteria of our institution such as:

          1. A lidocaine allergy

          2. Copper allergy

          3. Current cervicitis

          4. Pelvic inflammatory disease (PID) within 3 months

          5. Uterine anomalies

          6. Pain medication within 6 hours before insertion

          7. Misoprostol administration within 24 hour before insertion

          8. History of cervical surgery and contraindication to study medications.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Menoufia University</name>
      <address>
        <city>Shebin Elkom</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>nabih elkholy, MD</last_name>
      <phone>00201060868443</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alhayah national hospital</name>
      <address>
        <city>Abha</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>mohamed maher</last_name>
      <phone>+966558198655</phone>
    </contact>
    <contact_backup>
      <last_name>tarek sayyed</last_name>
    </contact_backup>
    <investigator>
      <last_name>mohamed maher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2015</study_first_submitted>
  <study_first_submitted_qc>August 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2015</study_first_posted>
  <last_update_submitted>June 21, 2016</last_update_submitted>
  <last_update_submitted_qc>June 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Al Hayat National Hospital</investigator_affiliation>
    <investigator_full_name>mohamed maher</investigator_full_name>
    <investigator_title>assistant professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

